<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

How to Use Mouse Clinical Trials to Reinterpret Clinical Results

how to use mouse clinical trial advanced analysis to reinterpret clinical resultsExplore how to use mouse clinical trials and analysis by linear mixed models approaches to reinterpret clinical trial results, including failed trials and for biomarker validation.

Applications of Mouse Clinical Trial Analysis through a Linear Mixed Models Framework

Mouse clinical trials (MCTs) are population, Phase 2-like studies that more closely mimic clinical trials than other preclinical studies. Using panels of PDX models, MCTs provide highly predictive efficacy data and advise on responder/non-responder populations.

We’ve previously published the development of a linear mixed models (LMMs) approach for MCT analysis. This improves on current endpoint based analysis approaches, and has multiple applications including guiding MCT study design and accurate quantification of drug efficacy/effects.

LMM analysis is also useful for analyzing and reinterpreting clinical results, including for biomarker validation.

Using MCTs and LMM Analysis for Clinical Biomarker Validation

Clinical trials can sometimes throw up contradictory results. MCTs and LMM analysis can help to dig deeper into data and uncover the real trends. A good example of this looks at addressing a potential biomarker arising from clinical trials.

Two published clinical trials (Bamias et al and De Dosso et al) show a mismatch on whether ERCC1 is predictive of response to cisplatin in gastric cancer patients. This is despite the two trials having almost identical numbers of patients as well as p values from Kaplan-Meier survival analyses.

A LMM analysis of MCT cisplatin data across a panel of PDX was performed to start to address the issue. Alongside the PDX panel response to cisplatin, ERCC1 expression levels were also established by RNAseq. For the MCT panel of 42 PDX (including gastric, lung, and esophageal models) ERCC1 expression was wide ranging.

Tumor growth inhibition (TGI) data could then be separated out by models with high or low ERCC1 expression level. This analysis showed some interesting points:

  • Cisplatin treatment slowed tumor growth for both high and low ERCC1 expressing PDX.
  • The difference in magnitude between vehicle and cisplatin groups for high and low ERCC1 expressing PDX shows that cisplatin has a greater effect on the low ERCC1 expressing PDX.

Using MCTs and LMM Analysis for Clinical Biomarker Validation

This analysis goes some way to explaining the conflicting clinical results. PDX with low ERCC1 expression levels have faster tumor growth and benefit from cisplatin treatment. It should follow that ERCC1-negative patients would benefit more from cisplatin treatment, and would therefore have a worse prognosis if not treated.

Cisplatin treatment would improve their prognosis, but it’s not known if their overall prognosis is better than that of ERCC1-positive patients.

Applying MCTs and LMMs to Reinterpret Failed Clinical Trials

A main use of MCTs is to identify responder and non-responder subgroups within the preclinical setting, to improve patient stratification in the clinic. MCTs and LMM analysis can also be used to reassess failed clinical trials to look for specific patient subsets that might still benefit from treatment.

Cetuximab, an EGFR inhibitor, is known to induce a greater response in PDX with high EGFR expression or copy-number amplification. This was identified by correlating EGFR expression with cetuximab TGI data.

However, using an endpoint based analysis approach, like TGI, has limitations. This includes a dependency on calculation day, initial tumor volume difference between arms, and tumor growth rate. The actual correlation between TGI with efficacy is weak. However, if a LMM is applied to model a gene’s effects on tumor growth, it does still show that EGFR is the top ranked gene.

In the clinic, a randomized Phase 3 open label trial looked at the benefit of adding cetuximab to capecitabine-cisplatin for advanced gastric cancer patients. The paper found no additional benefits of adding cetuximab to this regimen.

The results can be reinterpreted though, specifically looking for patients with high EGFR protein expression scores (>200). This finds 29 people from the trial, 21 receiving only chemotherapy and 8 patients with added cetuximab. Looking at the survival results, a clear difference is observed for cetuximab addition:

  • Median PFS of 4 months for patients on chemotherapy alone vs 8 months with cetuximab addition.
  • Median OS of 10.1 months for patients on chemotherapy alone vs 19.5 months with cetuximab addition.

For this distinct subset of patients, it appears that cetuximab does provide clinical benefit, rescuing this subset from the failed clinical trial.


Mouse clinical trials and sophisticated analyses provide a solution for assessing conflicting clinical data, and close analysis of failed clinical trials. For potential biomarkers, MCTs provide an ideal study type for the job, allowing measurement of tumor growth with vehicle treatment.

Related Posts